Regeneron wins over $400M jury award as Amgen found liable in antitrust case

1 month ago 2

• Healthcare

BrianAJackson/iStock via Getty Images

A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen (NASDAQ:AMGN) violated U.S. antitrust laws by forcing pharmacy benefit managers ((PBMs)) to select its cholesterol drug Repatha over the former’s rival drug

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Regeneron wins over $400M jury award as Amgen found liable in antitrust case